» Articles » PMID: 33846818

Inhibitory Effects of Terrein on Lung Cancer Cell Metastasis and Angiogenesis

Overview
Journal Oncol Rep
Specialty Oncology
Date 2021 Apr 13
PMID 33846818
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer metastasis is the leading cause of mortality in cancer patients. Over 70% of lung cancer patients are diagnosed at advanced or metastatic stages, and this results in an increased incidence of mortality. Terrein is a secondary bioactive fungal metabolite isolated from . Numerous studies have demonstrated that terrein has anticancer properties, but in the present study, the cellular mechanisms underlying the inhibition of lung cancer cell metastasis by terrein was investigated for the first time. Using MTT assays, the cytotoxic effects of terrein were first examined in human lung cancer cells (A549 cells) and then compared with its cytotoxic effects in three noncancer control cell lines (Vero kidney, L6 skeletal muscle and H9C2 cardiomyoblast cells). The results indicated that terrein significantly reduced the viability of all these cells but exhibited a different level of toxicity in each cell type; these results revealed a specific concentration range in which the effect of terrein was specific to A549 cells. This significant cytotoxic effect of terrein in A549 cells was verified using LDH assays. It was then demonstrated that terrein attenuated the proliferation of A549 cells using IncuCyte image analysis. Regarding its antimetastatic effects, terrein significantly inhibited A549 cell adhesion, migration and invasion. In addition, terrein suppressed the angiogenic processes of A549 cells, including vascular endothelial growth factor (VEGF) secretion, capillary‑like tube formation and VEGF/VEGFR2 interaction. These phenomena were accompanied by reduced protein levels of integrins, FAK, and their downstream mediators (e.g., PI3K, AKT, mTORC1 and P70S6K). All these data indicated that terrein was able to inhibit all the major metastatic processes in human lung cancer cells, which is crucial for cancer treatment.

Citing Articles

Chemical Constituents of the Deep-Sea-Derived MCCC 3A00169 and Their Antiproliferative Effects.

Zou Z, Zhang G, Zhou Y, Xie C, Xie M, Xu L Mar Drugs. 2022; 20(12).

PMID: 36547883 PMC: 9781865. DOI: 10.3390/md20120736.


Terrien, a metabolite made by , has activity against .

Cadelis M, Grey A, van de Pas S, Geese S, Weir B, Copp B PeerJ. 2022; 10:e14239.

PMID: 36275475 PMC: 9586122. DOI: 10.7717/peerj.14239.


Novel Angiogenic Regulators and Anti-Angiogenesis Drugs Targeting Angiogenesis Signaling Pathways: Perspectives for Targeting Angiogenesis in Lung Cancer.

Li Y, Lin M, Wang S, Cao B, Li C, Li G Front Oncol. 2022; 12:842960.

PMID: 35372042 PMC: 8965887. DOI: 10.3389/fonc.2022.842960.

References
1.
Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L . Signal transduction by vascular endothelial growth factor receptors. Biochem J. 2011; 437(2):169-83. DOI: 10.1042/BJ20110301. View

2.
Burridge K, Guilluy C . Focal adhesions, stress fibers and mechanical tension. Exp Cell Res. 2015; 343(1):14-20. PMC: 4891215. DOI: 10.1016/j.yexcr.2015.10.029. View

3.
Niu G, Chen X . Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets. 2010; 11(8):1000-17. PMC: 3617502. DOI: 10.2174/138945010791591395. View

4.
Liu L, Li F, Cardelli J, Martin K, Blenis J, Huang S . Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene. 2006; 25(53):7029-40. DOI: 10.1038/sj.onc.1209691. View

5.
Qi H, Xin L, Xu X, Ji X, Fan L . Epithelial-to-mesenchymal transition markers to predict response of Berberine in suppressing lung cancer invasion and metastasis. J Transl Med. 2014; 12:22. PMC: 3944941. DOI: 10.1186/1479-5876-12-22. View